close

Fenwick Represents Oncothyreon in $50 Million At-The-Market Offering

June 03, 2016

​​Fenwick & West represented Oncothyreon Inc. (NAS: ONTY), a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer, in an at-the-market offering of its common stock having an aggregate value of up to $50 million. The offering was made pursuant to an effective shelf registration statement previously filed with the SEC.

Cowen and Company, LLC acted as sales agent for the offering.

The Fenwick transaction team included corporate partners Effie Toshav, Alan Smith and James Evans and associate Amanda Rose.